Table 2 Incidence of thromboembolic toxicity in prospective studies using cisplatin

Keys et al. [5] (cervix)

Cis 40 mg/m² q wk X 6 concurrent

75 Gy to pt A

0 deaths 1 Grade 3&1 Grade 4 CVT (NOS)

Benedetti et al. [3] (cervix)

Cis 40–80 mg/m² q wk X 6–8 concurrent

45–50 Gy WP 20–30 Gy Low Dose Rate

0 deaths

Morris et al. [2] (cervix)

Cis 75 mg/m² and 5-FU 4000 mg/m² q wk X 3 concurrent

85 Gy to pt A

1 death (NOS)

Pearcey et al. [6] (cervix)

Cis 40 mg/m² q wk X 5 concurrent

80 Gy to pt A

1 death (SBP) 3 Grade 3 CVT (NOS)

Peters et al. [7] (cervix)

Cis 70 mg/m² and 5-FU 1000 mg/m² q wk X 4 concurrent

4930 WP @ 170 cGy/day

1 death (Bilateral ureteral obstruction)

Rose et al. [8] (cervix)

Cis 40 mg/m² q wk X 6 concurrent or Cis/5-FU/Hydroxyurea or Hydroxyurea

80 Gy to pt A

0 deaths 2 Grade 3 CVT (NOS), with 3 drug regimen

Malfetano et al. [4] (cervix)

Cis 1 mg/Kg q wk with XRT

45 Gy PA, WP 4–5000 cGy and 3–4000 cGy Low Dose Rate

2 Grade 5 CVT (from PE)